# 04_QA_REPORT — PP-0180 Gastric Cancer Molecular Classification

## Identity

- **PP ID:** PP-0180
- **Title:** Gastric Cancer Molecular Classification
- **QA Report ID:** QA-PP-0180
- **Version:** 1.0.0
- **QA Date:** 2026-08-09
- **Status:** PASS — GOLD — READY FOR INTEGRATION

## QA Executive Summary

PP-0180 was produced after the complete Decision Batch was approved and locked.

The package was checked against:

- CORE_WORKING_RULES v1.6;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0;
- PP Registry;
- approved Discussion depth/format reference;
- supplied gastric-cancer clinical source materials;
- adjacent package ownership.

The absolute full-depth rule was applied. The package was not compacted or shortened below the approved Gold reference standard.

---

# Layer 1 — Content QA

## 1.1 Scope respected

**PASS**

The package is dedicated to gastric cancer molecular classification.

It does not silently expand into:

- detailed histopathology;
- detailed Lauren classification;
- detailed WHO taxonomy;
- detailed molecular-subtype biology;
- individual biomarker testing;
- NGS laboratory methodology;
- variant interpretation;
- hereditary testing;
- individualized treatment.

## 1.2 Completeness

**PASS**

The CKO contains:

- metadata;
- educational objectives;
- scope;
- included/not included;
- **40 independent clinical knowledge blocks**;
- patient explanations;
- clinical importance;
- key concepts;
- evidence anchors;
- **15 common misconceptions**;
- key messages;
- knowledge graph;
- revision history.

The block architecture deliberately preserves full depth rather than compressing clinically distinct molecular questions.

## 1.3 Core molecular framework coverage

**PASS**

The package explicitly covers:

- molecular classification;
- molecular heterogeneity;
- genome instability;
- MSI;
- CIN;
- EBV-positive group;
- genomically stable group;
- TCGA framework;
- four broad TCGA groups.

## 1.4 Classification hierarchy

**PASS**

The package clearly distinguishes:

**Histopathology**

→ **Lauren Classification**

→ **Molecular Classification**

→ **Individual Biomarker / Molecular Testing**

→ **Molecular Subtypes**

→ **Genomic Report Interpretation**

This preserves the project architecture.

---

# Layer 2 — Clinical QA

## 2.1 Guideline anchoring

**PASS**

NCCN v2.2026 explicitly states that pathologic review and biomarker testing contribute to diagnosis, classification and molecular characterization, and describes genetic aberrations and genome instability in gastric carcinogenesis. fileciteturn31file13

## 2.2 TCGA framework control

**PASS**

TCGA is used as a foundational molecular-classification framework.

The package does not falsely claim that every patient is routinely assigned a TCGA subtype by a single clinical test.

NCCN cites the TCGA comprehensive molecular characterization study. fileciteturn31file15

## 2.3 Biomarker overreach control

**PASS**

The package does not equate:

- HER2 with molecular subtype;
- PD-L1 with molecular subtype;
- CLDN18.2 with molecular subtype;
- MSI with the entire molecular classification.

NCCN explicitly notes that CLDN18.2 positivity can be independent of established molecular subtypes such as dMMR and HER2 status. fileciteturn31file0

## 2.4 NGS overreach control

**PASS**

NGS is presented as a molecular testing technology.

The package does not reproduce laboratory workflows, sequencing chemistry, bioinformatic pipelines or variant-calling procedures.

ESMO-ASCO emphasizes assay scope and distinctions among panel, exome and genome-wide sequencing. fileciteturn30file7

## 2.5 Somatic/germline control

**PASS**

The package clearly distinguishes tumor-acquired somatic alterations from inherited germline alterations.

NCI separately addresses hereditary gastric-cancer genetics. fileciteturn29file5

## 2.6 Treatment overclaim control

**PASS**

The package states that molecular findings can have treatment relevance but do not independently determine treatment.

NCCN demonstrates that specific biomarkers are integrated with clinical setting and treatment pathways. fileciteturn30file10turn31file12

## 2.7 Prognostic overclaim control

**PASS**

The package does not use molecular classification as a standalone individualized prognostic algorithm.

---

# Layer 3 — Educational QA

## 3.1 Patient-facing clarity

**PASS**

Technical concepts are introduced with plain-language explanations.

## 3.2 Terminology control

**PASS**

The package distinguishes:

- molecular classification;
- molecular subtype;
- biomarker;
- genomic alteration;
- NGS;
- somatic finding;
- germline finding.

## 3.3 Logical flow

**PASS**

The CKO follows:

**definition**

→ **rationale**

→ **heterogeneity**

→ **genome instability**

→ **TCGA framework**

→ **four broad groups**

→ **biomarkers**

→ **NGS**

→ **specimen/assay limitations**

→ **somatic vs germline**

→ **precision oncology**

→ **limitations**

→ **patient interpretation**.

## 3.4 Misconception control

**PASS**

Fifteen common misconceptions are explicitly addressed.

## 3.5 Full-depth compliance

**PASS — ABSOLUTE**

The standing golden rule was applied:

> **Approved Gold reference depth is the minimum. Never compact or shorten the artifact. Equal depth is required; deeper is permitted where clinically justified.**

No compacted or abbreviated production package was created.

---

# Layer 4 — Governance QA

## 4.1 Four-artifact structure

**PASS**

Exactly four governed Markdown artifacts are included:

1. 01_CKO.md
2. 02_KNOWLEDGE_PASSPORT.md
3. 03_PRIMARY_EVIDENCE_PACKAGE.md
4. 04_QA_REPORT.md

## 4.2 Gold Specification compliance

**PASS**

The package follows the locked four-artifact Gold architecture:

- Clinical Knowledge Object;
- Knowledge Passport;
- Primary Evidence Package;
- QA Report.

The Source Files explicitly require this stable artifact architecture and prohibit redesign. fileciteturn28file3turn28file13

## 4.3 Source-first compliance

**PASS**

The PP identity, scope, evidence base and adjacent boundaries were reviewed from project Source Files before production.

## 4.4 User-controlled sequence

**PASS**

PP-0180 was produced only after explicit user approval/lock of the Decision Batch.

No automatic progression to PP-0181 occurred.

## 4.5 Boundary compliance

**PASS**

The final production Boundary uses the required four-part structure:

- Core
- Supporting
- Explicitly Excluded
- Delegated-to PP

The project governance explicitly requires this ownership-oriented Boundary in the final artifact-production response. fileciteturn28file13

## 4.6 ZIP naming

**PASS**

The ZIP filename contains both:

- PP number;
- package title.

## 4.7 Repository readiness

**PASS**

The package is ready for integration.

---

# QA Traceability Matrix

| Requirement | Result |
|---|---|
| Correct PP identity | PASS |
| Approved scope used | PASS |
| Absolute full-depth rule | PASS |
| CKO structure | PASS |
| Knowledge Passport | PASS |
| Primary Evidence Package | PASS |
| QA Report | PASS |
| Molecular classification definition | PASS |
| Molecular heterogeneity | PASS |
| Genome instability | PASS |
| MSI | PASS |
| EBV-positive | PASS |
| Genomically Stable | PASS |
| Chromosomal Instability | PASS |
| TCGA framework | PASS |
| Molecular classification vs Lauren | PASS |
| Molecular classification vs biomarker | PASS |
| Molecular classification vs NGS | PASS |
| Somatic vs germline | PASS |
| Assay scope | PASS |
| Specimen limitations | PASS |
| Precision-oncology context | PASS |
| Treatment overclaim control | PASS |
| Prognostic overclaim control | PASS |
| PP-0180 vs PP-0188 boundary | PASS |
| PP-0180 vs PP-0181–0187 boundary | PASS |
| PP-0180 vs PP-0189 boundary | PASS |
| Evidence traceability | PASS |
| Knowledge Graph | PASS |
| Boundary | PASS |
| Four-artifact ZIP | PASS |
| ZIP filename includes title | PASS |
| Repository readiness | PASS |

# Final Boundary

**Boundary: Core = gastric cancer molecular classification as a molecular-biology layer of tumor characterization; molecular heterogeneity; rationale for molecular classification; relationship with histopathology and Lauren classification; genome instability; high-level TCGA framework and the four broad groups EBV-positive, MSI, genomically stable (GS), and chromosomal instability (CIN); conceptual genomic alteration types; relationship between molecular classification, biomarker testing, genomic testing and precision oncology; high-level clinical relevance; specimen/assay limitations; molecular heterogeneity and interpretation limits; Supporting = foundational DNA/gene/chromosome concepts, somatic-versus-germline distinction, high-level molecular-group/biomarker relationships, NGS as a conceptual technology, specimen adequacy, molecular tumor-board context, tumor evolution and patient-facing molecular terminology; Explicitly Excluded = detailed Lauren or WHO classification, detailed TCGA subtype biology, exhaustive molecular-subtype profiles, HER2/MSI/MMR/PD-L1/CLDN18.2/TMB/FGFR2 testing methodology, NGS laboratory methodology, variant interpretation, genomic-report interpretation, germline testing and genetic counseling, individualized prognosis, individualized treatment selection, treatment algorithms, ctDNA/MRD/resistance monitoring and recurrence-monitoring algorithms; Delegated-to PP = PP-0168 EBV-associated Gastric Cancer + EBV Testing, PP-0178 Histopathologic Classification, PP-0179 Lauren Classification, PP-0037 WHO Classification, PP-0181–PP-0187 HER2/MSI/MMR/PD-L1/CLDN18.2/TMB/FGFR2/NGS Testing, PP-0188 Molecular Subtypes of Gastric Cancer, PP-0189 Genomic Test Results / How to Read a Molecular Report, PP-0190–PP-0191 Biomarker Testing for Targeted Therapy/Immunotherapy, hereditary/germline packages, and downstream molecular monitoring and treatment packages.**

# Final QA Decision

## **PASS — GOLD — READY FOR INTEGRATION.**

PP-0180 is complete, source-grounded, full-depth, structurally compliant, boundary-controlled, and ready for integration.
